| abstract |
Novel dihydropyrimidines or the isomeric form thereof, wherein R<1> = pyridyl, pyrimidinyl, thiazolyl or oxazolyl, wherein said radicals can be substituted up to three times by halogen and/or C1-C6-alkyl, R<2>= C6-C10-aryl or 5-10 membered heteroaryl, wherein said aryl or heteroaryl radicals can be respectively substituted by one to three substituents from the group of C1-C6alkyl, C1-C6-alkoxycarbonyl, halogen, nitro, polyfluoro-C1-C4-alkyl, R3 = C1-C14-alkyl, wherein one to two carbon atoms can be substituted in the chain thereof by oxygen or sulphur and/or the C1-C14 -alkyl radical can be substituted by one to three substitutents from the group of hydroxy, cyano, NR<6>R<7>, C1-C6- alkoxycarbonyl, C6-C10-aryl, 5-10 membered heteroaryl, wherein C6-C10-aryl and 5-10 membered heteroaryl can be substituted by one to three substituents from the group of hydroxy, C1-C6-alkoxycarbonyl, halogen, halogen- C1-C6-alkyl and X = C1-C3-alkylene which can be interrupted by oxygen and/or substituted by C1-C6 aryl. The invention also relates to combinations of novel dihydropyrimidines and combinations thereof with other antiviral agents, suitable for combating HBV infections. |